Life Science News

RSS

Bruker acquires Center for Tribology

Bruker Corporation today announced the closing of its acquisition of Center for Tribology, Inc. (CETR) for $13 million in cash as an initial purchase price, with potential additional earn-out payments of up to $4 million in cash, depending on growth and profitability of the CETR-business within Bruker in 2012 and 2013.

From Bruker Nano Surfaces and Metrology 13 Oct 2011

Roche launches LightCycler Nano real-time PCR system in the U.S.

Roche announced today the U.S. launch of the latest addition to the company's real-time PCR portfolio of LightCycler instruments for use in research, the LightCycler Nano real-time PCR system.

From Roche Sequencing and Life Science 13 Oct 2011

Illumina, UNTHSC enter next-generation sequencing collaboration in forensic DNA analysis

Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.

From Illumina, Inc. 4 Oct 2011

Roche to sponsor 3rd Annual World MRSA Day

As part of its ongoing work in the prevention and control of serious infections in healthcare settings, Roche announced today its sponsorship of the 3rd Annual World MRSA Day.

From Roche Sequencing and Life Science 29 Sep 2011

Thermo Fisher Scientific cassette cuts tissue embedding time in half

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific SecureSette, a new cassette for histology laboratories that reduces embedding time by 50 percent. The innovative design of new SecureSette™ cassettes makes embedding extremely simple; tissues are orientated during grossing and the cassette is not opened during embedding. An integral sponge securely holds tissue in place during processing which not only improves orientation, but also reduces the time spent re-embedding incorrectly aligned samples by more than half. The result is a more efficient workflow, higher quality and improved patient safety without the need to purchase additional equipment.

From Thermo Fisher Scientific Inc. 20 Sep 2011

TJUH adopts new equipment from Roche Diagnostics for laboratory testing services

Thomas Jefferson University Hospital (TJUH) is advancing its laboratory testing services with new state-of-the-art equipment from Roche Diagnostics designed to help labs increase their testing capacity and deliver reliable results with greater efficiency.

From Roche Sequencing and Life Science 20 Sep 2011

MRG reports 6.5% annual growth in the US and European endoscope market through 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the overall United States and European endoscope market will show a sustained growth averaging 6.5 percent per year through 2015, primarily driven by strong growth in the large GI endoscope segment, but also seeing notable growth in cameras.

From Evident Corporation - Life Sciences 8 Sep 2011

Pall inaugurates new Singapore Life Sciences Centre of Excellence

Pall Corporation, a global leader in filtration, separation and purification, today inaugurated its Pall Life Sciences Centre of Excellence in Singapore, the latest addition to the company's global customer support network.

From Pall Corporation 8 Sep 2011

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Labcyte Inc., a leader in miniaturization technologies for liquid handling, announced today that Thermo Fisher Scientific, the world leader in serving science, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates.

From Thermo Fisher Scientific Inc. 7 Sep 2011

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Roche Diagnostics terminates sales and distribution agreement with Response

Response Biomedical Corporation today announced that Roche Diagnostics has terminated, effective September 30, 2011, the sales and distribution agreement between Roche and Response dated June 25, 2008. Under the terms of that agreement and related agreements, Roche Diagnostics had agreed to distribute Response's cardiovascular point-of-care (POC) tests on the RAMP® 200 Reader in the US.

From Roche Sequencing and Life Science 2 Sep 2011

Alcon chooses Bruker ContourGT-X8 Optical Surface Profiler

Bruker announced today that Alcon Corporation has selected the Bruker ContourGT-X8 Optical Surface Profiler to provide non-destructive, non-contact reference metrology for critical dimensioning and 3D characterization of Alcon's current and next-generation intra-ocular lenses.

From Bruker Nano Surfaces and Metrology 30 Aug 2011

ProteinSimple introduces automated Western Blot

ProteinSimple today introduced a revolutionary new system for protein analysis, Simon and the Simple Western. The Simple Western is a complete reinvention of the Western Blot, and is truly a historic breakthrough for protein research.

From ProteinSimple 30 Aug 2011

QIAGEN acquires Cellestis

QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.

From QIAGEN Manchester Limited 29 Aug 2011

Thermo Fisher acquires Phadia

Thermo Fisher Scientific Inc., the world leader in serving science, today reported that it has completed its previously announced acquisition of Phadia, a global leader in blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases.

From Thermo Fisher Scientific Inc. 24 Aug 2011

Federal Circuit affirms dismissal of Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020.

From Illumina, Inc. 22 Aug 2011

Pittsburgh researchers combine Viscotek GPC and Zetasizer Nano in work on novel polymers for drug delivery

Molecular weight and molecular weight distribution measurements are a basic necessity in studying the synthesis of the novel polymers being carried out by researchers at the Department of Bioengineering at the University of Pittsburgh. For the Pittsburgh team, the applications and technical expertise provided by Malvern Panalytical is a significant factor in their use of the company’s Viscotek gel permeation chromatography (GPC) system to characterize polymer molecular weight, prior to applying the Zetasizer Nano for zeta potential measurements to study inter-molecular interactions.

From Malvern Panalytical 18 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Illumina and University of Oxford collaborate to sequence whole genomes

Illumina, Inc. today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes.

From Illumina, Inc. 3 Aug 2011

Illumina board authorizes new $100 million share repurchase program

Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.

From Illumina, Inc. 3 Aug 2011